Selected article for: "antiviral therapy and clinical management"
Author: White, Nicholas J.; Webster, Robert G.; Govorkova, Elena A.; Uyeki, Timothy M.
Title: What Is the Optimal Therapy for Patients with H5N1 Influenza?
  • Cord-id: ldoqyqlg
  • Document date: 2009_6_23
    • ID: ldoqyqlg
    Snippet: In a 2007 article in PLoS Medicine [10], Holger J. Schünemann and colleagues described a new process used by the World Health Organization for rapidly developing clinical management guidelines in emergency situations. These situations include outbreaks of emerging infectious diseases. The authors discussed how they developed such a “rapid advice” guideline for the pharmacological management of avian influenza A (H5N1) virus infection. The guideline recommends giving the antiviral drug oselt
    Document: In a 2007 article in PLoS Medicine [10], Holger J. Schünemann and colleagues described a new process used by the World Health Organization for rapidly developing clinical management guidelines in emergency situations. These situations include outbreaks of emerging infectious diseases. The authors discussed how they developed such a “rapid advice” guideline for the pharmacological management of avian influenza A (H5N1) virus infection. The guideline recommends giving the antiviral drug oseltamivir at a dose of 75 mg twice daily for five days. In this Debate, Nicholas White argues that such dosing is inadequate, Robert Webster and Elena Govorkova say that combination antiviral therapy should be used, and Tim Uyeki reminds us that clinical care of patients with H5N1 entails much more than antiviral treatment. These issues may also apply to therapy of patients hospitalized with severe disease due to novel swine-origin influenza A (H1N1) virus infection.

    Search related documents:
    Co phrase search for related documents
    • active site and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and additional research: 1, 2
    • active site and loading dose: 1
    • active site residue and acute respiratory syndrome: 1, 2
    • acute respiratory distress syndrome and additional research: 1, 2, 3
    • acute respiratory distress syndrome and adequate oxygen delivery: 1, 2, 3
    • acute respiratory distress syndrome and loading dose: 1, 2, 3, 4
    • acute respiratory distress syndrome and long course: 1, 2, 3, 4, 5, 6
    • acute respiratory syndrome and additional research: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additive efficacy: 1, 2
    • acute respiratory syndrome and adequate oxygen delivery: 1, 2, 3
    • acute respiratory syndrome and administration antiviral treatment: 1, 2, 3, 4
    • acute respiratory syndrome and loading dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and long course: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20